[1] 张明玺, 罗俊. H型高血压的病因及发病机制[J]. 心血管病学进展, 2012,33(2):253-256.
[2] 李建平, 卢新政, 霍勇, 等. H型高血压诊断与治疗专家共识[J]. 中华高血压杂志, 2016,24(2):123-127.
[3] 张朝当, 徐希平. H 型高血压2.0——药物研发与脑卒中精准预防[J]. 药学进展, 2019,43(8):567-575.
[4] Huo Y, Li J, QIN X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China[J]. JAMA, 2015,313(13):1325.
[5] Hu S, REN L, Wang Y, et al. Homocysteine-lowering therapy and early functional outcomes of ischemic patients with H-type hypertension: a retrospective analysis of CNSR[J]. Australasian Physical & Engineering Sciences in Medicine, 2015,38(4):785-791.
[6] Jacques PF, Rosenberg IH, Rogers G, et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from The Third National Health and Nutrition Examination Survey1- 4[J]. Am J Clin Nutr, 1999,69(3):482-489.
[7] Hao L, Ma J, Zhu J, et al. High prevalence of hyperhomocysteinemia in Chinese adults is associated with low folate, vitamin B-12, and vitamin B-6 status[J]. J Nutr, 2007,137(2):407-413.
[8] Franco RF, Araújo AG, Guerreiro JF,et al. Analysis of the 677 C → T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups[J]. Thromb Haemost, 1998,79(1):119-121.
[9] Robinson K, Arheart K, Refsum H,et al. Low circulating folate and vitamin B6 concentrations:risk factors for stroke, peripheral vascular disease, and coronary artery disease [J]. Circulation, 1998,97(5):437-443.
[10] Sood HS, Hunt MJ, Tyagi SC. Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia[J]. American Journal of Physiology-Lung Cellular and Molecular Physiology, 2003,284(2):L333-L341.
[11] 王佳, 王淑玲, 曾丹, 等. 亚甲基四氢叶酸还原酶C677T基因多态性与H型高血压及同型半胱氨酸水平升高的相关性研究[J]. 中国脑血管病杂志, 2015,12(11):581-586.
[12] 钱净, 施茜, 翟秀伟, 等. 昆明地区汉族H型高血压MTHFR基因C677T多态性及其相关危险因素的分析[J]. 检验医学, 2018,33(6):476-480.
[13] 李蕊, 杨柳, 苏明权, 等. MTHFR基因多态性及血浆同型半胱氨酸水平与心脑血管疾病的相关性分析[J]. 检验医学, 2016,31(10):922-924.
[14] 邹卓群, 仲怀琴, 李金鹆, 等. 上海市某院2015年体检人群H型高血压的患病率及其影响因素分析[J]. 安徽医学, 2017,38(11):1440-1444.
[15] 吴瑕玉. 同型半胱氨酸代谢途径关键酶基因多态性及维生素B6缺乏与乳腺癌遗传易感性关系研究[D]. 昆明: 云南大学, 2013.
[16] Montezano AC, Touyz RM. Reactive oxygen species, vascular noxs, and hypertension: Focus on translational and clinical research[J]. Antioxidants & Redox Signaling, 2014,20(1):164-182.
[17] Young CN, Cao X, Guruju MR, et al. ER stress in the brain subfornical organ mediates angiotensin-dependent hypertension[J]. Journal of Clinical Investigation, 2012,122(11):3960-3964.
[18] Parris MK. Integrated brain restoration after ischemie stroke-medical management, risk factors, nutrients, and other interventions for managing inflammation and enhancing brain plasticity[J]. Altern Med Rev, 2009,14(01):14-35.
[19] Waid DS, Morris JK, Wald NJ. Reconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysis[J]. PloS one, 2011,6(2):e16473.
[20] 华敏, 郝冬琳, 沈华超, 等. 同型半胱氨酸血症与脑卒中的关系分析[J]. 中国实用神经疾病杂志, 2013,16(22):70-71.
[21] Cui R, Moriyama Y, Koike KA, et al. Serum total homocysteine concentrations and risk of mortality from stroke and coronary heart disease in Japanese: The JACC study[J]. Atherosclerosis, 2008,198(2):412-418.
[22] 邵华, 高鑫, 苏汉文, 等. 血浆同型半胱氨酸与脑卒中的关系研究[J]. 卒中与神经疾病, 2011,18(4):208-209.
[23] 张素荣, 陈志刚, 吕风华, 等. 冠心病和高血压血浆同型半胧氨酸及内皮素的变化[J]. 中国危重病急救医学, 2005,17(5):309.
[24] 刘玉薇, 万楠. 血清同型半胱氨酸水平与冠心病相关性研究[J]. 国际检验医学杂志, 2018,39(19):2373-2375.
[25] 刘小艳, 刘涛. 同型半胱氨酸及其代谢酶基因多态性与冠心病的关系[J]. 中国动脉硬化杂志, 2018,26(1):55-59.
[26] 齐宏, 黄珊, 马祥生, 等. 同型半胱氨酸、高敏C反应蛋白及胱抑素C和脂蛋白相关磷脂酶A2与冠心病的相关性[J]. 广东医学, 2014,52(14):2253-2256.
[27] 董少英. 冠心病心力衰竭患者的血浆同型半胱氨酸水平与QRS波时限的相关性研究[D]. 郑州: 郑州大学, 2013.
[28] 林养, 陈梅, 林荣华, 等. 血清同型半胱氨酸对高血压早期肾损伤的诊断价值[J]. 海南医学院学报, 2012,18(10):1421-1422.
[29] Muntner P, Hamm LL, Kusek JW, et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease[J]. Annals of Internal Medicine, 2004,140(1):9.
[30] 高颖. 叶酸对H型高血压同型半胱氨酸水平和主要心血管事件的影响[J]. 当代医学, 2019,25(17):102-104.
[31] Bhargava S, Ali A, Bhargava EK, et al. Lowering homocysteine and modifying nutritional status with folic acid and vitamin B12 in Indian patients of vascular disease[J]. Journal of Clinical Biochemistry and Nutrition, 2012,50(3):222-226.
[32] Hankey GJ. B vitamins for stroke prevention[J]. Stroke and Vascular Neurology, 2018,3(2):51-58.
[33] 李建平, 霍勇, 刘平, 等. 马来酸依那普利叶酸片降压、降同型半胱氨酸的疗效和安全性[J]. 北京大学学报:医学版, 2007,39(6):614-618.
[34] 张苾薇. 依那普利叶酸片在H型轻中度原发性高血压患者治疗中的应用效果观察[J]. 中国医药指南, 2019,17(7):38-39.
[35] 文海英, 赖小文, 黄楷森. 依那普利联合叶酸治疗老年H型高血压病对患者炎性因子及血管内皮功能的影响[J]. 临床误诊误治, 2019,32(2):22-26.
[36] 阴其云. 依那普利联用叶酸治疗H型高血压的临床疗效及对血管内皮功能的影响分析[J]. 中国实用医药, 2019,14(2):11-13.
[37] 王喆, 宋德明, 郑元喜, 等. 苯磺酸氨氯地平叶酸片治疗H型高血压疗效观察[J]. 安徽医药, 2017,21(7):1290-1294.
[38] Wang X, Qin X, DEMIRTAS H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis[J]. Lancet, 2007,369(9576):1876-1882.
[39] Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China[J]. JAMA, 2015,313(13):1325.
[40] Wang W, Wang X, Zhang Z, et al. A Meta-analysis of folic acid in combination with anti-hypertension drugs in patients with hypertension and hyperhomocysteinemia[J]. Frontiers in Pharmacology, 2017,8:585.
[41] Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease[J]. JAMA Internal Medicine, 2016,176(10):1443.
[42] Li Y, Qin X, Luo L, et al. Folic acid therapy reduces the risk of mortality associated with heavy proteinuria among hypertensive patients[J]. Journal of Hypertension, 2017,35(6):1302-1309. |
